Literature DB >> 14732627

Multiminicore disease in a family susceptible to malignant hyperthermia: histology, in vitro contracture tests, and genetic characterization.

Sandrine Guis1, Dominique Figarella-Branger, Nicole Monnier, David Bendahan, Geneviève Kozak-Ribbens, Jean-Pierre Mattei, Joël Lunardi, Patrick J Cozzone, Jean-François Pellissier.   

Abstract

BACKGROUND: Histological anomalies associated with malignant hyperthermia (MH) have been scarcely reported. In some patients susceptible to MH (MHS), central cores have been identified and a genetic association has been proposed, but multiminicore lesions have not been systematically reported.
OBJECTIVE: To analyze the association between multiminicores and MHS in a large family with MH with an approach combining histology, in vitro contracture tests, and genetic analysis. PATIENTS AND METHODS: Twenty-nine members of an MH family (147 members) were investigated. MAIN OUTCOME MEASURES: Muscle biopsy specimens were analyzed histologically and with in vitro contracture tests. Genetic analyses were performed to determine the presence of mutations in the ryanodine receptor (RYR1) gene.
RESULTS: According to the gold standard in vitro contracture tests, 17 patients were diagnosed as having MHS and 10 as not being susceptible. Multiminicores were found in 16 of the 17 MHS patients and in a single nonsusceptible participant. A linkage between the MH trait and the RYR1 locus in chromosome 19 was demonstrated, whereas no already known mutations were found. Two missense heterozygous mutations (R2676W and T2787S) were identified from sequencing of the entire coding complementary DNA. Overall, we found a significant association between MHS and the presence of multiminicores (chi(2) = 26.5, P<.001) on the one hand and the presence of new mutations in the RYR1 gene (chi(2) = 19.0, P<.001) on the other hand. This remarkably high occurrence of multiminicores in an MHS family is uncommon, and genetic analyses indicate that the association between multiminicores and MHS is linked to a novel R2656W and T2787S substitution present on the same allele of the RYR1 gene.
CONCLUSIONS: These results indicate that multiminicore lesions are observed in MHS patients with neither clinical signs related to multiminicore disease nor histological features of congenital myopathies. These multiminicore lesions may be secondary to mutations in the RYR1 gene. As a consequence, these patients must be distinguished from patients with multiminicore disease and from other MHS patients for whom multiminicores are not observed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14732627     DOI: 10.1001/archneur.61.1.106

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  11 in total

1.  The pore structure of the closed RyR1 channel.

Authors:  Steven J Ludtke; Irina I Serysheva; Susan L Hamilton; Wah Chiu
Journal:  Structure       Date:  2005-08       Impact factor: 5.006

Review 2.  Endoplasmic reticulum Ca(2+) handling in excitable cells in health and disease.

Authors:  Grace E Stutzmann; Mark P Mattson
Journal:  Pharmacol Rev       Date:  2011-07-07       Impact factor: 25.468

3.  RYR1 and CACNA1S genetic variants identified with statin-associated muscle symptoms.

Authors:  Paul J Isackson; Jianxin Wang; Mohammad Zia; Paul Spurgeon; Adrian Levesque; Jonathan Bard; Smitha James; Norma Nowak; Tae Keun Lee; Georgirene D Vladutiu
Journal:  Pharmacogenomics       Date:  2018-10-16       Impact factor: 2.533

Review 4.  Novel regulators of RyR Ca2+ release channels: insight into molecular changes in genetically-linked myopathies.

Authors:  A F Dulhunty; N A Beard; P Pouliquin; T Kimura
Journal:  J Muscle Res Cell Motil       Date:  2006-08-15       Impact factor: 2.698

5.  A novel late-onset axial myopathy associated with mutations in the skeletal muscle ryanodine receptor (RYR1) gene.

Authors:  Sissel Løseth; Nicol C Voermans; Torberg Torbergsen; Sue Lillis; Christoffer Jonsrud; Sigurd Lindal; Erik-Jan Kamsteeg; Martin Lammens; Marcus Broman; Gabriele Dekomien; Paul Maddison; Francesco Muntoni; Caroline Sewry; Aleksandar Radunovic; Marianne de Visser; Volker Straub; Baziel van Engelen; Heinz Jungbluth
Journal:  J Neurol       Date:  2013-01-18       Impact factor: 4.849

6.  RYR1 mutations as a cause of ophthalmoplegia, facial weakness, and malignant hyperthermia.

Authors:  Sherin Shaaban; Leigh Ramos-Platt; Floyd H Gilles; Wai-Man Chan; Caroline Andrews; Umberto De Girolami; Joseph Demer; Elizabeth C Engle
Journal:  JAMA Ophthalmol       Date:  2013-12       Impact factor: 7.389

7.  Genetic mutations associated with susceptibility to perioperative complications in a longitudinal biorepository with integrated genomic and electronic health records.

Authors:  Nicholas J Douville; Sachin Kheterpal; Milo Engoren; Michael Mathis; George A Mashour; Whitney E Hornsby; Cristen J Willer; Christopher B Douville
Journal:  Br J Anaesth       Date:  2020-09-03       Impact factor: 9.166

8.  A double mutation of the ryanodine receptor type 1 gene in a malignant hyperthermia family with multiminicore myopathy.

Authors:  Seul-Ki Jeong; Dong-Chan Kim; Yong-Gon Cho; Il-Nam Sunwoo; Dal-Sik Kim
Journal:  J Clin Neurol       Date:  2008-09-30       Impact factor: 3.077

9.  A case report of malignant hyperthermia in a patient with myotonic dystrophy type I: A CARE-compliant article.

Authors:  Seon Woo Yoo; Seon Ju Baek; Dong-Chan Kim; A Ram Doo
Journal:  Medicine (Baltimore)       Date:  2021-06-11       Impact factor: 1.817

Review 10.  Malignant hyperthermia.

Authors:  Henry Rosenberg; Mark Davis; Danielle James; Neil Pollock; Kathryn Stowell
Journal:  Orphanet J Rare Dis       Date:  2007-04-24       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.